Glenmark Pharma surges as its arm receives final USFDA approval for two ANDA

01 Mar 2012 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 311.90, up by 3.70 points or 1.20% from its previous closing of Rs. 308.20 on the BSE.

The scrip opened at Rs. 310.00 and has touched a high and low of Rs. 313.90 and Rs. 309.15 respectively. So far 12021 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 351.20 on 26-Jul-2011 and a 52 week low of Rs. 255.00 on 15-Mar-2011.

Last one week high and low of the scrip stood at Rs. 315.00 and Rs. 303.35 respectively. The current market cap of the company is Rs. 8408.96 crore.

The promoters holding in the company stood at 48.29% while Institutions and Non-Institutions held 39.29% and 12.42% respectively.

Glenmark Generics Incorporation, USA, a subsidiary of Glenmark Generics, has received final approval for two abbreviated new drug application’s (ANDA’s) from the United States Food and Drug Administration (USFDA). The approvals are for Ciclopirox Gel 0.77% and Levonorgestrel & Ethinyl Estradiol tablets USP, 0.15 mg/0.03 mg. Glenmark will market this approved oral contraceptive as Marlissa tablets and plans to commence shipping both products immediately.

Ciclopirox Gel 0.77% is the generic version of Loprox Gel, 0.77%, of Medicis Pharmaceutical Corporation. Ciclopirox Gel is indicated for the topical treatment of seborrheic dermatitis of the scalp and is available in 30, 45, and 100 gram tube presentations. According to IMS Health sales data for the 12 month period ending September 2011, Ciclopirox Gel garnered annual sales of greater than $10 million.

Marlissa tablets are Glenmark's generic version of Nordette tablets by Duramed Pharmaceuticals. Marlissa tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. According to IMS Health for the 12 month period ending September 2011 total market sales achieved for Levonorgestrel and Ethinyl Estradiol tablets USP, 0, 15 mg/0.03 mg were approximately $ 50.84 million. This approval marks Glenmark's eight female hormonal product authorized for distribution by the USFDA.

Glenmark's current portfolio consists of 76 products authorized for distribution in the US marketplace. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

Glenmark Generics (GGL) is a subsidiary of Glenmark Pharmaceuticals (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries.

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×